PD-1 mechanism of action: What do we know?

Dr. Adil Daud

University of California

Dr. Adil Daud, MBBS, is an expert in immunotherapy and has pioneered the development of novel immunotherapeutics and targeted therapies. His fellowship in medical oncology was at the Memorial Sloan Kettering Cancer Center and he was a faculty member at the Moffitt Cancer Center in Tampa, Florida. Dr. Daud is currently Professor of Medicine and Dermatology at the University of California, San Francisco, and is the director of the Melanoma Program and melanoma clinical research at the Helen Diller Family Cancer Center at UCSF. He led the development of IL-12 in melanoma and has developed novel technology to deliver it in vivo. He has played a major role in developing PD-1 antibodies in cancer therapy and recently he has developed novel assays to determine immune responsiveness in vivo. These assays can determine the likelihood of response to immunotherapy and provide novel insights into immune drug development. Dr. Daud has collaborated on numerous clinical and translational clinical trials that have yielded insights into the use of immunotherapy.